GO:0045910 negative regulation of DNA recombination: Regulatory Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045910 (negative regulation of DNA recombination) describes any process that stops, prevents, or reduces the frequency, rate or extent of DNA recombination.
• Key negative regulators include FIGNL1-FIRRM, which prevents DNA damage-independent RAD51 and DMC1 loading during meiosis, and CDK12/CDK13, whose inhibition suppresses homologous recombination repair in triple-negative breast cancer.
• The E2A proteins (TCF3) provide positive and negative regulation of V(D)J recombination, illustrating context-dependent control.
• G-quadruplex DNA and RNA structures modulate class switch recombination in B-lymphocytes, contributing to negative regulation.
• Post-translational modifications such as crotonylation of RPA1 by CDYL regulate homologous recombination-mediated DNA repair.
• Dysregulation of negative regulation of DNA recombination is linked to cancer, genomic instability, and therapy resistance, making it a target for CRISPR-based functional studies [2,7].
Description
DNA recombination is a fundamental biological process that generates genetic diversity, repairs DNA double-strand breaks, and ensures proper chromosome segregation during meiosis. However, uncontrolled or aberrant recombination can lead to genomic instability, chromosomal rearrangements, and cancer. To maintain genomic integrity, cells have evolved intricate mechanisms to negatively regulate DNA recombination, ensuring that recombination occurs only at the right time, place, and frequency. The Gene Ontology term GO:0045910, negative regulation of DNA recombination, captures these inhibitory processes that stop, prevent, or reduce the frequency, rate or extent of DNA recombination. Understanding this regulatory network is critical for researchers studying genome stability, meiosis, immune diversity, and cancer therapeutics [4,5]. Recent studies have identified diverse molecular players, including FIGNL1-FIRRM, CDK12/CDK13, E2A proteins, and CDYL, that negatively regulate recombination through distinct mechanisms [2,4,5,8]. This article provides a comprehensive overview of GO:0045910, integrating authoritative QuickGO data with verified PubMed literature to support research-grade investigations.
negative regulation of DNA recombination At A Glance
| GO ID | GO:0045910 |
|---|---|
| GO term | negative regulation of DNA recombination |
| Ontology | biological_process |
| Synonym | down regulation of DNA recombination, down-regulation of DNA recombination, downregulation of DNA recombination, inhibition of DNA recombination |
| Major function | Stops, prevents, or reduces the frequency, rate or extent of DNA recombination |
| Related processes | Homologous recombination, V(D)J recombination, class switch recombination, DNA repair |
| Key regulators | FIGNL1-FIRRM, CDK12/CDK13, E2A proteins, CDYL, RPA1 |
| Disease relevance | Cancer, genomic instability, therapy resistance |
What Is GO:0045910?
According to the Gene Ontology, GO:0045910 (negative regulation of DNA recombination) is defined as any process that stops, prevents, or reduces the frequency, rate or extent of DNA recombination. This biological process encompasses molecular events that inhibit the exchange of genetic material between DNA molecules, including homologous recombination, V(D)J recombination, and class switch recombination. Negative regulation can occur at multiple levels, such as preventing the loading of recombinases like RAD51 and DMC1 onto DNA, modulating the stability of homologous recombination repair mRNAs, or altering the post-translational modification status of recombination factors. The term is a child of negative regulation of DNA metabolic process and regulation of DNA recombination, and it is essential for maintaining genomic stability and preventing inappropriate recombination events [1,3].
Why Is negative regulation of DNA recombination Important in Cell Biology?
Negative regulation of DNA recombination is crucial for preserving genomic integrity and preventing deleterious recombination events that can lead to cancer and other diseases [1,2]. In meiosis, precise control of recombination is essential for proper chromosome segregation, and its dysregulation can cause infertility and aneuploidy. In the immune system, negative regulation of V(D)J and class switch recombination ensures antibody diversity while avoiding autoimmunity and lymphomagenesis [5,6]. Moreover, cancer cells often exploit negative regulators of homologous recombination to resist DNA-damaging therapies, making these processes attractive therapeutic targets [2,7]. Understanding GO:0045910 provides insights into fundamental biology and offers opportunities for CRISPR-based functional genomics and drug discovery.
• Maintains genomic stability by preventing inappropriate or excessive DNA recombination.
• Ensures proper meiotic recombination and chromosome segregation, impacting fertility.
• Regulates immune diversity by controlling V(D)J and class switch recombination [5,6].
• Influences cancer therapy response, particularly PARP inhibitor sensitivity in triple-negative breast cancer [2,7].
• Involved in DNA repair pathway choice, affecting homologous recombination vs. non-homologous end joining.
• Post-translational modifications like crotonylation modulate recombination factor activity.
• Provides targets for CRISPR knockout, point mutation, and overexpression studies to dissect gene function [2,4].
• Dysregulation is associated with genomic instability syndromes and tumorigenesis [1,2].
• Offers biomarkers for predicting response to DNA-damaging agents.
• Enables synthetic lethality approaches in cancer with homologous recombination defects.
What Happens During negative regulation of DNA recombination?
Prevention of Recombinase Loading
In simple terms: Cells stop recombination by blocking the proteins that start the process from getting onto DNA.
A primary mechanism of negative regulation of DNA recombination is the prevention of recombinase loading onto DNA. FIGNL1-FIRRM is essential for meiotic recombination and prevents DNA damage-independent RAD51 and DMC1 loading, thereby negatively regulating recombination. Similarly, the regulation of DNA strand exchange in homologous recombination involves factors that inhibit the formation of presynaptic filaments. This step ensures that recombination initiates only when appropriate, avoiding spurious recombination events.
Modulation of mRNA Stability of HRR Factors
In simple terms: Cells can reduce recombination by degrading the messages that make recombination proteins.
Negative regulation can occur post-transcriptionally through the modulation of mRNA stability of homologous recombination repair (HRR) factors. Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer, acting as a negative regulator of recombination. This mechanism allows rapid adjustment of recombination capacity in response to cellular stress or therapeutic intervention.
Post-translational Modification of Recombination Proteins
In simple terms: Chemical tags added to recombination proteins can turn them off or change their activity.
Post-translational modifications play a critical role in negatively regulating DNA recombination. Global crotonylome analysis revealed that CDYL-regulated RPA1 crotonylation is involved in homologous recombination-mediated DNA repair. This modification can alter protein-protein interactions and DNA binding, thereby inhibiting recombination. Such dynamic modifications provide a reversible switch for recombination control.
Transcriptional and Developmental Control
In simple terms: Cells can turn recombination on or off by controlling the genes that encode recombination machinery.
Negative regulation of DNA recombination is also achieved through transcriptional and developmental control. The E2A proteins (TCF3) provide positive and negative regulation of V(D)J recombination, demonstrating that transcription factors can both promote and inhibit recombination in a context-dependent manner. Additionally, G-quadruplex DNA and RNA structures modulate class switch recombination in B-lymphocytes, contributing to negative regulation. These layers of control ensure that recombination occurs only in specific cell types or developmental stages [5,6].
Inhibition by CDK12/CDK13 in Cancer
In simple terms: Certain kinases can suppress recombination, and blocking them makes cancer cells more sensitive to drugs.
CDK12 and CDK13 are negative regulators of homologous recombination in triple-negative breast cancer. Therapeutic targeting of CDK12/CDK13 inhibits homologous recombination repair, leading to increased sensitivity to PARP inhibitors and platinum-based chemotherapy. This highlights how negative regulation of DNA recombination can be exploited therapeutically.
Key Genes Involved in GO:0045910 negative regulation of DNA recombination
The following genes and proteins are key players in the negative regulation of DNA recombination, as supported by verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FIGNL1 | Prevents DNA damage-independent RAD51 and DMC1 loading during meiosis | Meiotic recombination, fertility, genome stability |
| FIRRM | Partners with FIGNL1 to inhibit recombinase loading | Meiosis, DNA repair |
| CDK12 | Negatively regulates homologous recombination; inhibition sensitizes to PARP inhibitors | Triple-negative breast cancer therapy |
| CDK13 | Negatively regulates homologous recombination; target in cancer | Triple-negative breast cancer therapy |
| TCF3 (E2A) | Provides positive and negative regulation of V(D)J recombination | Immune diversity, lymphomagenesis |
| CDYL | Regulates RPA1 crotonylation, affecting homologous recombination | DNA repair, post-translational modification |
| RPA1 | Single-stranded DNA-binding protein; crotonylation modulates HR | Homologous recombination, DNA repair |
| Jab1 (COPS5) | Regulates HRR mRNA stability, modulating PARP inhibitor sensitivity | Triple-negative breast cancer, mRNA stability |
| RAD51 | Central recombinase; negative regulators prevent its loading | Homologous recombination, cancer [1,4] |
| DMC1 | Meiosis-specific recombinase; inhibited by FIGNL1-FIRRM | Meiotic recombination |
| G-quadruplex structures | DNA/RNA secondary structures that modulate class switch recombination | B-lymphocyte biology, class switch recombination |
| BRCA1 | Tumor suppressor involved in HR; negative regulation affects pathway choice | Cancer, DNA repair |
| BRCA2 | Mediates RAD51 loading; negative regulators counteract its function | Cancer, DNA repair |
| PALB2 | Links BRCA1 and BRCA2; negative regulation impacts HR | Cancer, DNA repair |
| RAD51AP1 | Stimulates RAD51-mediated strand exchange; subject to negative regulation | Homologous recombination |
| BLM | Helicase that resolves recombination intermediates; can negatively regulate | Genome stability, Bloom syndrome |
| RECQL5 | Helicase that negatively regulates homologous recombination | Genome stability, cancer |
How Is negative regulation of DNA recombination Regulated?
The negative regulation of DNA recombination is itself tightly regulated at multiple levels. Transcriptional control by E2A proteins modulates V(D)J recombination. Post-translational modifications, such as crotonylation of RPA1 by CDYL, dynamically regulate homologous recombination. mRNA stability of HRR factors is controlled by Jab1, affecting PARP inhibitor sensitivity. Additionally, CDK12/CDK13 kinase activity negatively regulates homologous recombination, and their inhibition is a therapeutic strategy. G-quadruplex structures in DNA and RNA provide another layer of regulation for class switch recombination. These regulatory mechanisms ensure that recombination is suppressed when not needed and activated appropriately [1,3].
negative regulation of DNA recombination and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CDK12 | Triple-negative breast cancer, therapy resistance | Knockout in TNBC cell lines, xenograft models |
| CDK13 | Triple-negative breast cancer | Knockout or point mutation in cancer cell lines |
| FIGNL1 | Meiotic failure, infertility | Knockout mouse models, spermatocyte cultures |
| TCF3 (E2A) | B-cell lymphoma, immune deficiency | Conditional knockout mice, B-cell lines |
| CDYL | Cancer, DNA repair defects | Knockout cell lines, crotonylation assays |
Cancer and Therapy Resistance
Dysregulation of negative regulation of DNA recombination is critically linked to cancer. In triple-negative breast cancer, inhibition of CDK12/CDK13 suppresses homologous recombination, creating a synthetic lethal interaction with PARP inhibitors. Jab1-mediated regulation of HRR mRNA stability modulates PARP inhibitor sensitivity, highlighting the clinical relevance of post-transcriptional control. Loss of negative regulators can lead to hyper-recombination and genomic instability, promoting tumorigenesis.
Meiotic Disorders and Infertility
FIGNL1-FIRRM is essential for meiotic recombination and prevents DNA damage-independent RAD51 and DMC1 loading. Disruption of this negative regulatory mechanism can cause aberrant recombination, meiotic arrest, and infertility. Understanding these processes is vital for reproductive biology and potential therapeutic interventions.
Immune Dysregulation and Lymphoma
Negative regulation of V(D)J and class switch recombination is essential for immune diversity and preventing autoimmunity. E2A proteins provide both positive and negative regulation of V(D)J recombination, and their dysregulation can lead to lymphoid malignancies. G-quadruplex structures modulate class switch recombination in B-lymphocytes, and their perturbation may contribute to B-cell disorders.
From negative regulation of DNA recombination-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate homologous recombination? | CRISPR knockout in HEK293T or U2OS cells, DR-GFP reporter assay |
| Does a point mutation in gene X affect its ability to inhibit recombination? | CRISPR point mutation knock-in in cancer cell lines |
| Does overexpression of gene X suppress recombination? | Doxycycline-inducible overexpression in TNBC cells |
| Where does protein X localize during meiosis? | Tagged knock-in (e.g., GFP) in mouse germ cells |
| Does gene X regulate V(D)J recombination? | Knockout in pre-B cell lines, V(D)J recombination substrate assays |
| Does gene X modulate class switch recombination? | Knockout in CH12F3 B lymphoma cells, IgA ELISA |
How to Study the negative regulation of DNA recombination Process
| Method | What It Measures | Typical Application |
|---|---|---|
| DR-GFP reporter assay | Homologous recombination frequency | Knockout validation, drug response |
| CRISPR knockout library screen | Genes affecting recombination or drug sensitivity | Discovery of negative regulators |
| Crotonylome profiling | Global crotonylation of proteins | Post-translational regulation of HR |
| Single-molecule imaging | RAD51/DMC1 filament formation | Mechanism of FIGNL1-FIRRM |
| V(D)J recombination assay | V(D)J recombination frequency | E2A regulation studies |
| Class switch recombination assay | IgA or IgG production | G-quadruplex modulation |
| mRNA stability assay | Half-life of HRR transcripts | Jab1 regulation |
| Bioinformatics pathway analysis | Enrichment of recombination genes | CRISPR screen data interpretation |
Homologous Recombination Reporter Assays
The DR-GFP and EJ5-GFP reporter systems are widely used to measure homologous recombination frequency. Knockout of candidate negative regulators, such as CDK12, leads to increased HR activity, which can be quantified by flow cytometry. These assays are essential for functional validation of genes identified in CRISPR screens.
CRISPR Library Screening
Genome-wide CRISPR knockout or activation screens can identify negative regulators of DNA recombination. For example, screens in PARP inhibitor-treated cells can uncover genes whose loss sensitizes or confers resistance, revealing negative regulators like CDK12. Bioinformatics analysis of screen data prioritizes candidate genes for follow-up.
Proteomics and Post-translational Modification Analysis
Global crotonylome analysis identified CDYL-regulated RPA1 crotonylation in homologous recombination. Mass spectrometry-based proteomics can map post-translational modifications on recombination factors, providing mechanistic insights into negative regulation.
Imaging and Single-Molecule Analysis
Fluorescence microscopy and single-molecule imaging can visualize the loading of RAD51 and DMC1 onto DNA. FIGNL1-FIRRM prevents DNA damage-independent loading, which can be observed using tagged proteins and live-cell imaging. These techniques reveal spatiotemporal dynamics of negative regulation.
How CRISPR Can Be Used to Study GO:0045910 negative regulation of DNA recombination
Knockout
CRISPR knockout is used to delete negative regulators of DNA recombination, such as CDK12 or FIGNL1, to assess their impact on recombination frequency and drug sensitivity [2,4]. Knockout cell lines are valuable for dissecting pathway function and validating screening hits.
Point Mutation
Point mutation knock-in allows precise modification of residues critical for negative regulation, such as phosphorylation sites or crotonylation sites on RPA1. This approach distinguishes catalytic activity from scaffolding functions and reveals mechanistic details.
Knock-in
Tagged knock-in (e.g., GFP, HA, or BirA) enables visualization and proteomic analysis of negative regulators in their endogenous context. Knock-in of reporter genes, such as DR-GFP, provides quantitative readouts of recombination.
Overexpression
CRISPR activation or cDNA overexpression can elevate levels of negative regulators to test whether they suppress recombination. Overexpression models are useful for studying dosage effects and identifying dominant-negative phenotypes.
How EDITGENE Supports negative regulation of DNA recombination Research
Researchers studying negative regulation of DNA recombination-related genes often need to determine whether a candidate gene is causally involved in suppressing recombination, and whether its loss or modification alters genomic stability, drug sensitivity, or immune diversity. EDITGENE provides comprehensive CRISPR-based services to accelerate these investigations, from knockout and point mutation to knock-in and overexpression models, as well as library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of DNA recombination research.
Frequently Asked Questions About negative regulation of DNA recombination
What is negative regulation of DNA recombination (GO:0045910)?
It is any biological process that stops, prevents, or reduces the frequency, rate or extent of DNA recombination, as defined by the Gene Ontology.
What genes are involved in negative regulation of DNA recombination?
Key genes include FIGNL1, FIRRM, CDK12, CDK13, TCF3 (E2A), CDYL, RPA1, and Jab1, among others [2,4,5,7,8].
How does FIGNL1 negatively regulate recombination?
FIGNL1, in complex with FIRRM, prevents DNA damage-independent loading of RAD51 and DMC1 onto DNA during meiosis.
What is the role of CDK12 in homologous recombination?
CDK12 negatively regulates homologous recombination; its inhibition sensitizes triple-negative breast cancer cells to PARP inhibitors.
How is negative regulation of DNA recombination studied?
Common methods include DR-GFP reporter assays, CRISPR knockout screens, crotonylome profiling, and single-molecule imaging [2,4,8].
What diseases are associated with dysregulated negative regulation of DNA recombination?
Cancer, infertility, and immune disorders are linked to defects in this process [2,4,5].
Can CRISPR be used to study negative regulation of DNA recombination?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect gene function in this pathway [2,4,8].
What is the role of E2A proteins in V(D)J recombination?
E2A proteins provide both positive and negative regulation of V(D)J recombination, influencing immune diversity.
How does CDYL regulate homologous recombination?
CDYL regulates RPA1 crotonylation, which modulates homologous recombination-mediated DNA repair.
What is the clinical relevance of Jab1 in breast cancer?
Jab1 regulates HRR mRNA stability, affecting PARP inhibitor sensitivity in triple-negative breast cancer.
Conclusion
GO:0045910 (negative regulation of DNA recombination) encompasses a diverse set of molecular mechanisms that safeguard genomic integrity by preventing inappropriate recombination. Key regulators such as FIGNL1-FIRRM, CDK12/CDK13, E2A, and CDYL have been elucidated through CRISPR-based studies and advanced proteomics [2,4,5,8]. Dysregulation of these processes contributes to cancer, infertility, and immune disorders, making them attractive therapeutic targets [2,7]. Continued research using CRISPR models and bioinformatics will further unravel the complexities of this essential biological process.
References
- 1. Ito M et al.. 2024. Positive and negative regulators of RAD51/DMC1 in homologous recombination and DNA replication.. DNA Repair (Amst) 134:103613 PMID: 38142595
- 2. Quereda V et al.. 2019. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.. Cancer Cell 36(5):545-558.e7 PMID: 31668947
- 3. Holthausen JT et al.. 2010. Regulation of DNA strand exchange in homologous recombination.. DNA Repair (Amst) 9(12):1264-72 PMID: 20971042
- 4. Zainu A et al.. 2024. FIGNL1-FIRRM is essential for meiotic recombination and prevents DNA damage-independent RAD51 and DMC1 loading.. Nat Commun 15(1):7015 PMID: 39147779
- 5. Bain G et al.. 1999. Positive and negative regulation of V(D)J recombination by the E2A proteins.. J Exp Med 189(2):289-300 PMID: 9892611
- 6. Dézé O et al.. 2023. Roles of G4-DNA and G4-RNA in Class Switch Recombination and Additional Regulations in B-Lymphocytes.. Molecules 28(3) PMID: 36770824
- 7. Peng X et al.. 2025. Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer.. Mol Cancer 24(1):217 PMID: 40819058
- 8. Yu H et al.. 2020. Global crotonylome reveals CDYL-regulated RPA1 crotonylation in homologous recombination-mediated DNA repair.. Sci Adv 6(11):eaay4697 PMID: 32201722
